EC Number   |
Application |
Reference |
|---|
   3.4.24.11 | analysis |
the synthetic fluorogenic peptide substrate qf-Abeta(12-16)AAC is more sensitive to NEP than the previously reported peptide substrates, so that concentrations of NEP as low as 0.03 nM can be detected at peptide concentration of 0.002 mM. It can be used for high-throughput screening of compounds that upregulate NEP |
755120 |
| 3.4.24.11 | medicine |
CD10, i.e. beta-secretase, expression is detected in 62.2% of prostate cancer samples and occurs preferentially in higher Gleason pattern. CD10 expression positively correlates with adverse tumor features such as elevated preoperative prostate-specific antigen, higher Gleason score, and advanced stage. Prostate-specific antigen recurrence is significantly associated with the staining pattern of CD10 expression. Outcome significantly declines from negative over membranous, membranous-cytoplasmic, to exclusively cytoplasmatic CD10 expression. In multivariate analysis, CD10 expression is an independent predictor for prostate-specific antigen failure |
697378 |
| 3.4.24.11 | medicine |
engineered neprilysin can be a therapeutic for Alzheimer's disease due to its ability to degrade the peptide amyloid beta |
735116 |
| 3.4.24.11 | medicine |
expression of neprilysin on the surface of leukocytes in mouse model of Alzheimer's disease reduces soluble brain amyloid beta peptide levels by 30% and lowers the accumulation of amyloid beta peptides by 50-60% when transplantation is performed at both young and early adult age. Peripheral neprilysin expression reduces amyloid-dependent performance deficits as measured by the Morris water maze test. Neprilysin expression results in the catabolism of amyloid beta to small, innocuous peptide fragments |
699683 |
| 3.4.24.11 | medicine |
impaired cardiopulmonary vagal reflex control of heart rate is a feature of normal aging, and this deficit may be ameliorated by either atrium natriuretic peptide infusion or chronic neutral endopeptidase inhibition |
698207 |
| 3.4.24.11 | medicine |
in the Flemish variant of amyloid beta, resistance to degradation by nepriylsin may underlie the pathogenicity associated with the A21G mutantion in amyloid beta |
700415 |
| 3.4.24.11 | medicine |
NEP is a target for Entresto used in treatment of heart failure |
753262 |
| 3.4.24.11 | medicine |
neprilysin can reduce the size and number of Abeta deposits in a transgenic mouse model. Neprilysin gene transfer therapy or other methods to increase endogenous neprilysin activity have the potential to prevent the accumulation of the amyloid Abeta peptide and as such may be able to prevent or delay the onset of Alzheimer#s disease |
669913 |
| 3.4.24.11 | medicine |
overexpression neprilysin at low levels in transgenic mouse affects primarily the levels of neuropeptide Y compared with other neuropeptides. Neprilysin cleaves neuropeptide Y in C-terminal fragments, whereas silcencing neprilysin reduces neuropeptide Y processing. Infusion of the most abundant neuropeptide Y fragments 21-36 and 31-36 into the brain of amyloid precursor protein transgenic mice ameliorates the neurodegenerative pathology in this model. The amidated neuropeptide Y fragments protect human neuronal cultures from the neurotoxic effects of amyloid beta |
699693 |
| 3.4.24.11 | medicine |
overexpression of human neprilysin for 4 months in young amyloid precursor protein//DeltaPS1 double-transgenic mice results in reduction in amyloid beta peptide levels, attenuation of amyloid load, oxidative stress, and inflammation, and improved spatial orientation. The overall reduction in amyloidosis and associated pathogenetic changes in the brain results in decreased memory impairment by about 50% |
695449 |
